OMOP May Seek To Partner With Mini-Sentinel On Drug Safety, PCORI On Outcomes Research
Executive Summary
The drug industry-funded Observational Medical Outcomes Partnership may seek collaboration with high-profile public-private drug safety and comparative effectiveness research initiatives.
You may also be interested in...
PCORI Critics Emerge As Institute Formally Releases Draft Methods Report
As the Patient-Centered Outcomes Research Institute opens up the public comment period for the draft report created by the institute’s Methodology Committee, criticisms on the direction PCORI is moving are beginning to surface, including accusations that it is becoming just another AHRQ or NIH.
Mini Sentinel Data Covers 126 Million Patients; FDA Weighing Potential Uses For Drug Industry
With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.